表没食子儿茶素没食子酸酯预防肺癌放疗患者放射性食管炎的前瞻性三臂随机试验
这项II期研究将不可切除III期非小细胞肺癌或局限期小细胞肺癌患者随机分为预防性EGCG组(A组)、出现食管炎后治疗性EGCG组(B组)和常规治疗组(C组),共83例可评估毒性。三组最大食管炎分级差异有统计学意义(P=0.004),接受EGCG患者的最大急性放射性食管炎显著低于常规治疗者,A组平均食管炎指数低于B组,C组最高。
要点
- 三组最大食管炎分级差异有统计学意义(P=0.004),EGCG组最大急性放射性食管炎显著低于常规治疗组。
- 平均食管炎指数A组低于B组(P=0.028),B组低于C组(P=0.002),C组最高。
- 接受EGCG患者的疼痛指数和吞咽困难指数显著低于常规治疗患者。
核心结论
- 应用EGCG可有效减轻晚期肺癌急性放射性食管炎,且无明显副作用。
- 预防性应用EGCG在治疗急性食管炎方面较治疗性应用略有优势。
研究设计与样本
- 这是一项EGCG联合放化疗治疗不可切除III期非小细胞肺癌或局限期小细胞肺癌的II期研究。
- 患者被随机分为预防性EGCG组(A组)、出现食管炎后治疗性EGCG组(B组)或常规治疗组(C组)。
- 共83例患者符合毒性分析条件(A组 vs B组 vs C组:N=28:27:28)。
- 三组患者基线特征无显著差异。
- 每周记录食管炎分级、疼痛评分和吞咽困难评分,并计算调整后食管炎指数(AEI)、疼痛指数(API)和吞咽困难指数(ADI)以反映治疗全程变化。
主要发现
- 三组最大食管炎分级差异有统计学意义(P=0.004)。
- 接受EGCG患者的最大急性放射性食管炎显著低于常规治疗患者。
- 平均AEI:A组低于B组(P=0.028),B组低于C组(P=0.002),C组最高。
- 接受EGCG患者的API和ADI显著低于常规治疗患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This trial investigated whether epigallocatechin-3-gallate (EGCG), a radioprotector, could be effective in the prevention and treatment of acute radiation-induced esophagitis (ARIE). METHODS AND MATERIALS: This is a phase II study of EGCG combined with chemoradiation in unresectable stage III non-small-cell lung cancer or limited stage small cell lung cancer. Patients were randomized into a prophylactic EGCG group (arm A), a therapeutic EGCG group after the occurrence of esophagitis (arm B) or conventional therapy group (arm C). Esophagitis grades, pain and dysphagia scores were recorded weekly. Adjusted esophagitis index (AEI), pain index (API) and dysphagia index (ADI) were calculated to reflect changes in esophagitis grade, pain score and dysphagia score throughout treatment. RESULTS: A total of 83 patients were eligible for toxicity analysis (arm A vs arm B vs arm C: N = 28:27:28). There was no significant difference in the baseline characteristics among three arms of the patients. The difference in the maximum esophagitis grade among three groups was statistically significant (P = 0.004). The maximum ARIE for patients with EGCG was significantly lower than for those with conventional therapy. The mean AEI of arm A was lower than that of arm B, while the mean AEI of arm C was the highest (arm A vs arm B, P = 0.028; arm B vs arm C, P = 0.002). Furthermore, API and ADI were significantly lower in patients receiving EGCG than in conventionally treated patients. CONCLUSION: The application of EGCG could effectively alleviate acute radiation esophagitis in advanced lung cancer without obvious side effects. Prophylactic application of EGCG had a slight advantage over therapeutic use in treatment of acute esophagitis.
引用
- Zhao H, Jia L, Chen G, et al. A prospective, three-arm, randomized trial of EGCG for preventing radiation-induced esophagitis in lung cancer patients receiving radiotherapy. Radiother Oncol. 2019. PMID: 30898322. doi:10.1016/j.radonc.2019.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。